HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

ZYME — Zymeworks Inc.

ZYME (Zymeworks Inc.) stock: $29.63, $2.09B market cap, $322.5M cash, $1.77B EV, $2.10B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.

Source: 10-K FY2025 via SEC EDGAR

Share price
$29.63
Market cap
$2,088.2M
Cash
$322.5M
Enterprise value
$1,765.7M

Balance sheet

Cash$322.5M
Debt$0.0M
Net cash$322.5M
Enterprise value$1,765.7M
Basic shares71.0M shares
Fully diluted shares71.0M shares
Fully diluted market cap$2,102.5M
Cash per share$4.54
Quarterly burn$31.9M
Cash runway10.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common
71.0M
Pre-funded warrants
0.0M
Options
—
RSUs
—
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
71.0M

Cap table as of 2026-08-04.

Price history

Loading ZYME daily closes…

Loading price history…

Next catalyst

pasritamig · Est. Nov 7, 2026 · half midpoint · guided Now

Recently reported

ZW191 Phase 1 Positive · 2026-10-24
Primary: Confirmed objective response rate (cORR) in the randomized dose-optimization portion of the ongoing Phase 1 study of ZW191 in platinum-resistant ovarian cancer (PROC) — ZW191 demonstrated a cORR of 64.5% at 6.4 mg/kg and 55.3% at 9.6 mg/kg among response-evaluable patients with high-grade serous PROC, with disease control rates of 100% and 92.1%, respectively
· Median duration of response not yet reached at either dose; six-month progression-free survival (PFS) was 61% in both groups
· Median PFS was 7.9 months at 6.4 mg/kg and 9.8 months at 9.6 mg/kg in patients with high-grade serous PROC
· Confirmed objective response rates were 69.2% in patients with high FRα expression, 50.0% in patients with intermediate FRα expression and 55.0% in patients with low or negative FRα expression
· 80 patients with PROC randomized to receive ZW191 at 6.4 mg/kg (n=37) or 9.6 mg/kg (n=43) every three weeks, as of the September 10, 2026 data cutoff date
· Patients were heavily pretreated, having received a median of four prior lines of therapy, with 45% receiving five or more prior lines; median follow-up was seven months
Safety: Grade 3 or higher treatment-related adverse events occurred in 22% of patients receiving 6.4 mg/kg compared with 44% at 9.6 mg/kg; dose reductions in 5% and 33%, discontinuations due to adverse events in 14% and 19%; no deaths due to treatment-emergent adverse events were reported in either treatment group
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego